Vaxcyte, Inc. (NASDAQ:PCVX) Receives Consensus Recommendation of “Buy” from Analysts

Vaxcyte, Inc. (NASDAQ:PCVX) has been assigned a consensus recommendation of “Buy” from the eight brokerages that are currently covering the company, Marketbeat.com reports. Eight analysts have rated the stock with a buy rating. The average 1 year target price among brokers that have covered the stock in the last year is $145.71.

A number of brokerages have weighed in on PCVX. Cantor Fitzgerald reaffirmed an “overweight” rating on shares of Vaxcyte in a report on Wednesday, November 6th. The Goldman Sachs Group began coverage on Vaxcyte in a report on Friday, December 20th. They issued a “buy” rating and a $135.00 target price on the stock. Finally, Needham & Company LLC reaffirmed a “buy” rating and issued a $140.00 target price on shares of Vaxcyte in a report on Wednesday, November 6th.

Insider Transactions at Vaxcyte

In related news, CEO Grant Pickering sold 2,366 shares of the business’s stock in a transaction dated Thursday, November 7th. The stock was sold at an average price of $103.89, for a total value of $245,803.74. Following the completion of the sale, the chief executive officer now directly owns 137,398 shares of the company’s stock, valued at $14,274,278.22. The trade was a 1.69 % decrease in their position. The sale was disclosed in a filing with the SEC, which is available at the SEC website. Also, SVP Mikhail Eydelman sold 5,000 shares of the business’s stock in a transaction dated Thursday, December 5th. The shares were sold at an average price of $91.49, for a total value of $457,450.00. Following the completion of the sale, the senior vice president now directly owns 28,697 shares of the company’s stock, valued at $2,625,488.53. The trade was a 14.84 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last ninety days, insiders sold 113,732 shares of company stock valued at $11,730,787. Corporate insiders own 3.10% of the company’s stock.

Institutional Trading of Vaxcyte

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in PCVX. Natixis Advisors LLC boosted its stake in shares of Vaxcyte by 6.5% in the 2nd quarter. Natixis Advisors LLC now owns 14,091 shares of the company’s stock worth $1,064,000 after buying an additional 861 shares during the last quarter. CIBC Asset Management Inc purchased a new position in shares of Vaxcyte in the 2nd quarter worth approximately $228,000. Rhumbline Advisers boosted its stake in shares of Vaxcyte by 7.4% in the 2nd quarter. Rhumbline Advisers now owns 159,295 shares of the company’s stock worth $12,028,000 after buying an additional 11,001 shares during the last quarter. TD Asset Management Inc boosted its stake in shares of Vaxcyte by 11.1% in the 2nd quarter. TD Asset Management Inc now owns 312,426 shares of the company’s stock worth $23,591,000 after buying an additional 31,138 shares during the last quarter. Finally, Victory Capital Management Inc. boosted its stake in shares of Vaxcyte by 9.5% in the 2nd quarter. Victory Capital Management Inc. now owns 307,516 shares of the company’s stock worth $23,221,000 after buying an additional 26,641 shares during the last quarter. 96.78% of the stock is owned by institutional investors.

Vaxcyte Price Performance

Vaxcyte stock opened at $81.08 on Monday. The stock’s fifty day moving average price is $90.20 and its two-hundred day moving average price is $93.26. Vaxcyte has a one year low of $58.10 and a one year high of $121.06. The firm has a market cap of $10.11 billion, a PE ratio of -17.63 and a beta of 0.98.

Vaxcyte (NASDAQ:PCVX) last posted its quarterly earnings data on Tuesday, November 5th. The company reported ($0.83) EPS for the quarter, topping analysts’ consensus estimates of ($1.10) by $0.27. During the same period in the prior year, the business posted ($0.91) EPS. Sell-side analysts expect that Vaxcyte will post -4.14 earnings per share for the current fiscal year.

Vaxcyte Company Profile

Vaxcyte, Inc, a clinical-stage biotechnology vaccine company, develops novel protein vaccines to prevent or treat bacterial infectious diseases. Its lead vaccine candidate is VAX-24, a 24-valent investigational pneumococcal conjugate vaccine for the prevention of invasive pneumococcal disease. The company also develops VAX-31 to protect against emerging strains and to help address antibiotic resistance; VAX-A1, a novel conjugate vaccine candidate to prevent disease caused by Group A Streptococcus; VAX-PG, a novel protein vaccine candidate targeting keystone pathogen responsible for periodontitis; and VAX-GI to prevent Shigella, a bacterial illness.